Amryt Pharma Share Discussion Threads

[alphabravo321] 16/8/2016 13:19

Will it turn blue?!

[888icb] 16/8/2016 12:31

More on offer now @19.9p

[888icb] 16/8/2016 12:29

As you say very difficult to buy as the maximum on Barclays is 3000 @19p

[papillon] 16/8/2016 12:29

Jacksonpollack
14 Aug'16 - 21:19 - 283 of 290 0 0

Papillon. So cathal is telling porkies then? He said news flow from Q3 2016. Has he spoken to you to say that's not the case anymore?

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

I've NEVER, EVER, spoken to "Cathal". In fact I've NEVER, EVER, spoken to anybody from any company I've ever invested in!

What I posted on Sunday is happening as I predicted in my post 282.

[bigwavedave] 16/8/2016 12:17

Ok, there's one. Online bid now 18.75.

[bigwavedave] 16/8/2016 12:08

Wouldn't be surprised to see it tick back up. Can't buy any online. Offered 18.55 to sell.

[888icb] 16/8/2016 09:55

Fall is on low volume of 75000.

[currypasty] 16/8/2016 09:29

It was probably unreasonable to expect the price to continue to go up when no news arrived!

[888icb] 15/8/2016 08:20

A small uptick in the share price to start the day.

[risk1] 15/8/2016 08:17

Newsflow is coming!!

[jacksonpollack] 14/8/2016 21:19

Papillon. So cathal is telling porkies then? He said news flow from Q3 2016. Has he spoken to you to say that's not the case anymore?

[papillon] 14/8/2016 14:54

I don't think there's news on the way. AMYT just looks very, very, cheap compared with the potential of the drug soon to undergo phase III trials and by comparison to the US$800m a peer group rival in a similar field & position to AMYT fetched in the USA last year.

I expect a pull back soon, on profit taking, after such a big rise and a possible bullish Inverse Head & Shoulders chart pattern starting to form.

I think AMYT has the potential to be at least double the 24p placing price, possibly by the end of this year, or failing that early in 2017.

[alphabravo321] 13/8/2016 19:08

I wonder will see any snippets if info in tomorrows papers?

[888icb] 13/8/2016 09:30

Amryt raised £10 million at 24p per share in April when it listed on AIM. Those guys need it back to 24p before they can start to see a profit. The business and investment case hasn't changed since April. As news starts to arrive in the next quarter one would expect this to rise above 24p. A fairly rapid return to 24p in anticipation of news looks likely based on the last few days trading.

[saturn5] 13/8/2016 08:51

Just beware of a pump and dump

Chart looks like it.

This company has changed its name too often

[jacksonpollack] 13/8/2016 00:10

A sniper taken from Biotech and money in which Joe is interviewed about Amryt Pharma. Full interview on biotech and money . com. Q3 and Q4 2016 is news flow time and we are nearing the end of Q3 so expect to hear about entering into the €150 million market, imminently.

B&M: Joe please could you start with telling us your elevator pitch?
JW: Amryt is a new pharmaceutical company, set-up in August 2015. We develop drugs for orphan indications, meaning rare diseases. The business was set up initially to acquire assets in the orphan disease space. We recently acquired two companies with promising orphan drug candidates; Birkin, which is based in Germany and Som, which is based in Switzerland. Through these two acquisitions we have a pipeline of products.
We believe our lead product, Episalvan®, which is in late stage development for a rare, hereditary skin disorder called Epidermolysis Bullosa (EB), has been meaningfully de-risked following its European approval earlier this year for the treatment of Partial Thickness Wounds (PTWs). Episalvan® is expected to be launched in PTWs in late 2016, where it will represent a new category of advanced wound care management, a market worth in excess of €150 million.
We also have a promising pipeline of earlier stage orphan products and benefit from sales of our dermacosmetic product line, Imlan. We believe the combination of our sustainable core business with the significant potential upside of our orphan portfolio provides investors with an attractive risk/reward profile. We recently joined AIM and Dublin’s ESM following the reverse takeover of Fastnet Equity PLC, where we also raised £10m to accelerate the development of Episalvan® in EB.

[alphabravo321] 12/8/2016 20:19

Great week, what lies ahead? Nasdaq? Product Licensing deal?

[bigwavedave] 12/8/2016 16:16

For the past 3 months ave daily volume circa 170k. Today, close to 1m.

[nikki40] 12/8/2016 15:13

Ali I agree

[bigwavedave] 12/8/2016 15:10

I would expect that to happen on a +30% in one day not in one week.

[joesoap3] 12/8/2016 15:07

I know this is AIM and it may all be herd instinct and/or wild rumours but is there a point when the company are obliged to make the " we have no idea why " statement

[ali47fish] 12/8/2016 14:43

i want the news now to make a decision- what 's the use when it becomes toolate??

[big bull billy] 12/8/2016 14:40

Savage marked down by MMS after IPO.

Now they have all the shares they needed to bring it past 30p.